BACKGROUND The airways of obese asthmatics have been shown to be NO deficient, and this contributes to airway dysfunction and reduced response to inhaled corticosteroids. In cultured airway epithelial cells, L-citrulline, a precursor of L-arginine recycling and NO formation, has been shown to prevent asymmetric dimethyl arginine–mediated (ADMA-mediated) NO synthase (NOS2) uncoupling, restoring NO and reducing oxidative stress.METHODS In a proof-of-concept, open-label pilot study in which participants were analyzed before and after treatment, we hypothesized that 15 g/d L-citrulline for 2 weeks would (a) increase the fractional excretion of NO (FeNO), (b) improve asthma control, and (c) improve lung function. To this end, we recruited obese (BMI >30) asthmatics on controller therapy, with a baseline FeNO of ≤30 ppb from the University of Colorado Medical Center and Duke University Health System.RESULTS A total of 41 subjects with an average FeNO of 17 ppb (95% CI, 15–19) and poorly controlled asthma (average asthma control questionnaire [ACQ] 1.5 [95% CI, 1.2–1.8]) completed the study. Compared with baseline, L-citrulline increased whereas ADMA and arginase concentration did not (values represent the mean Δ and 95% CI): plasma L-citrulline (190 μM, 84–297), plasma L-arginine (67 μM, 38–95), and plasma L-arginine/ADMA (ratio 117, 67–167). FeNO increased by 4.2 ppb (1.7–6.7 ppb); ACQ decreased by –0.46 (–0.67 to 0.27 points); the forced vital capacity and forced exhalation volume in 1 second, respectively, changed by 86 ml (10–161 ml) and 52 ml (–11 to 132 ml). In a secondary analysis, the greatest FEV1 increments occurred in those subjects with late-onset asthma (>12 years) (63 ml [95% CI, 1–137]), in females (80 ml [95% CI, 5–154]), with a greater change seen in late-onset females (100 ml, [95% CI, 2–177]). The changes in lung function or asthma control were not significantly associated with the changes before and after treatment in L-arginine/ADMA or FeNO.CONCLUSION Short-term L-citrulline treatment improved asthma control and FeNO levels in obese asthmatics with low or normal FeNO. Larger FEV1 increments were observed in those with late-onset asthma and in females.TRIAL REGISTRATION ClinicalTrials.gov NCT01715844.FUNDING NIH NHLBI R01 HL146542-01.
Fernando Holguin, Hartmut Grasemann, Sunita Sharma, Daniel Winnica, Karen Wasil, Vong Smith, Margaret H. Cruse, Nancy Perez, Erika Coleman, Timothy J. Scialla, Loretta G. Que
Title and authors | Publication | Year |
---|---|---|
L-Arginine Supplementation in Severe Asthma
Shu-Yi Liao, Megan R. Showalter, Angela L. Linderholm, Lisa M. Franzi, Celeste Kivler, Yao Li, Michael R. Sa, Zachary A. Kons, Oliver Fiehn, Lihong Qi, Amir A. Zeki, Nicholas J. Kenyon |
JCI Insight | 2020 |
Metabolic Reprogramming: A Driver of Cigarette Smoke-Induced Inflammatory Lung Diseases
L Li, DC Yang, CH Chen |
Free radical biology & medicine | 2020 |
Mechanisms of non-type 2 asthma
SN Hudey, DK Ledford, JC Cardet |
Current Opinion in Immunology | 2020 |
A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19
Y Zhou, Y Hou, J Shen, R Mehra, A Kallianpur, DA Culver, MU Gack, S Farha, J Zein, S Comhair, C Fiocchi, T Stappenbeck, T Chan, C Eng, JU Jung, L Jehi, S Erzurum, F Cheng, N Soranzo |
PLoS Biology | 2020 |
A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19
Yadi Zhou, Yuan Hou, Jiayu Shen, Asha Kallianpur, Joe Zein, Daniel A Culver, Samar Farha, Suzy Comhair, Claudio Fiocchi, Michaela U Gack, Reena Mehra, Thaddeus Stappenbeck, Timothy Chan, Charis Eng, Jae U Jung, Lara Jehi, Serpil Erzurum, Feixiong Cheng |
ChemRxiv : the preprint server for chemistry | 2020 |
Physiological signature of late-onset nonallergic asthma of obesity.
Dixon AE, Peters U, Walsh R, Daphtary N, MacLean ES, Hodgdon K, Kaminsky DA, Bates JHT |
ERJ Open Research | 2020 |